Investors are more bearish on shares of the company of late if you consider the uptick in short interest. The company experienced a rise in short interest of 17.81% as of the latest report on August 31, 2017. Short shares grew 39,145 over that timeframe. Days to cover increased from 8.0 to 11.0 and the short interest percentage is 0.02% as of August 31.
Here are a few substantial investment firms who have updated their positions. Janus Capital Management LLC reduced its stake by selling 27,241 shares a decrease of 4.8% as of 03/31/2017. Janus Capital Management LLC claims 543,962 shares valued at $3,359,000. The value of the position overall is up by 4.1%. As of quarter end Creative Planning had acquired 300 shares growing its position 1.1%. The value of the investment in TRIL went from $161,000 to $116,000 decreasing 28.0% quarter to quarter.
Sectoral Asset Management Inc augmented its holdings by buying 55,000 shares an increase of 42.9%. Sectoral Asset Management Inc now holds 183,272 shares worth $806,000. The total value of its holdings increased 2.2%. As of the end of the quarter Victory Capital Management Inc had bought a total of 91,141 shares growing its holdings by 164.4%. The value in dollars increased from $313,000 to $645,000 a change of $332,000 for the reporting period.
H.C. Wainwright initiated coverage on the stock with a rating of “Buy”.
The company is unchanged by 0.00%% since yesterday’s close of 5.10. It is currently trading at $5.10 which is a tad above the 50 day moving average which is $4.65 and marginally under the 200 day moving average of $5.27. The 50 day moving average moved up $0.45 and the 200 day average moved down $-0.17.
As of the latest earnings report the EPS was $-3.96 and is estimated to be $-4.24 for the current year with 10,794,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.99 and the next full year EPS is projected to be $-3.07.
Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada..